Sanofi (NASDAQ:SNY) will begin shipping Beyfortus (nirsevimab) in early Q3 to ensure widespread availability ahead of the 2025–2026 respiratory syncytial virus (RSV) season, which typically runs from November through March.

Immunizations begin in early fall and these advance shipments provide